Komori
Governance4882Perseus Proteomics Inc.Pharmaceuticals

Articles of Incorporation 2026/06/24

As of 24 June 2026, the company expanded its business purposes and increased the total number of authorized shares from 24 million to 50 million. It also updated provisions concerning the terms of office of substitute directors, the method for selecting full-time Audit and Supervisory Committee members, shareholders meetings without a designated location, and the bodies authorized to decide on dividend payments and other distributions of surplus.

Worth reading
85Important
Scored from 1 of 5 sections
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
50000000
Total number of authorized shares
Wording
Definitive
How definitive the wording is.

Governance structure

Company with an Audit and Supervisory Committee
Number of directorsUp to 9 directors, excluding directors who are Audit and Supervisory Committee members, and up to 4 directors who are Audit and Supervisory Committee members. Number of outside directors: Not disclosed
Committee1
Audit and Supervisory Committee
Changes this time

Change to the business purposes; increase in the total number of authorized shares from 24,000,000 to 50,000,000; addition of provisions on the terms of office of substitute directors; change in the wording of the method for selecting full-time Audit and Supervisory Committee members; addition of provisions for shareholders meetings without a designated location; and establishment of provisions on the bodies authorized to decide on dividend payments and other distributions of surplus.

Governance structure
ItemDetails
Corporate Governance StructureCompany with an Audit and Supervisory Committee
Number of directorsUp to 9 directors, excluding directors who are Audit and Supervisory Committee members, and up to 4 directors who are Audit and Supervisory Committee members. Number of outside directors: Not disclosed
CommitteeAudit and Supervisory Committee (proportion of outside members: Not disclosed)
Changes this timeChange to the business purposes; increase in the total number of authorized shares from 24,000,000 to 50,000,000; addition of provisions on the terms of office of substitute directors; change in the wording of the method for selecting full-time Audit and Supervisory Committee members; addition of provisions for shareholders meetings without a designated location; and establishment of provisions on the bodies authorized to decide on dividend payments and other distributions of surplus.
Items this document does not state (4)
Number of independent officersPolicy on cross-shareholdingsTakeover defensesControlling shareholder

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The business purposes were revised to expand and clarify the scope of research and development, manufacturing, imports and exports, sales, and contract services. No reasons for the other changes are stated in the text.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Articles of Incorporation 2026/06/24 | Perseus Proteomics Inc. (4882) timely disclosure | Komori